Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 9/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL632258 | 0.82 | CASR (0.38) | CACNA2D1PDE10AOPRM1HTTCASR | |
| SCHEMBL8212417 | 0.76 | TAAR1 (0.60) | — | |
| SCHEMBL631702 | 0.71 | TAAR1 (0.34) | — | |
| SCHEMBL631933 | 0.70 | TAAR1 (0.46) | MAPT | |
| SCHEMBL632281 | 0.70 | TAAR1 (0.32) | — | |
| SCHEMBL632702 | 0.69 | CNR2 (0.48) | HTTKDM4EALDH1A1MAPT | |
| SCHEMBL632763 | 0.69 | GSK3B (0.35) | — | |
| SCHEMBL631906 | 0.68 | L3MBTL1 (0.38) | ALDH1A1 | |
| SCHEMBL631641 | 0.68 | GRM5 (0.34) | OPRM1 | |
| SCHEMBL632658 | 0.67 | KDM4E (0.43) | HTTPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586617-B2 | Aminomethyl-4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2076497-B1 | AMINOMETHYL-4-IMIDAZOLES | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | disclosed |
| EP-2076497-A1 | AMINOMETHYL-4-IMIDAZOLES | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-22 | — | — | US | disclosed |
| WO-2008046757-A1 | AMINOMETHYL-4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | INMT, HTR4, MC4R | CACNA2D1 1373/4885PDE10A 752/4885OPRM1 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.